Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels,…
News
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
This is the second deal announced between Rani and Celltrion, building upon a previously announced…
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
This is the second deal announced between Rani and Celltrion, building upon a previously announced…
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa.,…
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
– No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during…
Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…